STOCK TITAN
  1. Home
  2. Sec-filings
  3. SRTA
  4. [Form 4] Strata Critical Medical, Inc. Insider Trading Activity

Strata Critical Medical (SRTA) reports PSU vesting and tax share withholding

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Strata Critical Medical Co-CEO and CFO William A. Heyburn reported PSU-related equity activity. On July 30, 2026, he acquired 181,071 and 179,160 Class A common shares at no cost upon certification of performance-based RSU criteria. On July 31, 199,209 shares were withheld at about $5.09 per share to satisfy tax withholding obligations tied to this PSU vesting.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Heyburn William A.
Role Co-CEO and CFO
Type Security Shares Price Value
Tax Withholding Class A common stock, $0.0001 par value per share F3 199,209 $5.09 $1.01M
Grant/Award Class A common stock, $0.0001 par value per share F1 181,071 $0.00 $0.00
Grant/Award Class A common stock, $0.0001 par value per share F2 179,160 $0.00 $0.00
Holdings After Transaction: Class A common stock, $0.0001 par value per share — 1,710,019 shares (Direct)
Footnotes (3)
  1. F1. Represents shares that were acquired upon the certification of the Compensation Committee of the Issuer's Board of Directors of the satisfaction of performance criteria underlying an award of performance-based restricted stock units ("PSUs") granted to the Reporting Person on March 8, 2024.
  2. F2. Represents shares that were acquired upon the certification of the Compensation Committee of the Issuer's Board of Directors of the satisfaction of performance criteria underlying an award of performance-based restricted stock units ("PSUs") granted to the Reporting Person on March 20, 2025.
  3. F3. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of PSUs.
Shares from 2024 PSU award 181071 shares Class A common shares acquired 2026-07-30 upon certification of performance criteria for PSUs granted March 8, 2024
Shares from 2025 PSU award 179160 shares Class A common shares acquired 2026-07-30 upon certification of performance criteria for PSUs granted March 20, 2025
Shares withheld for taxes 199209 shares Shares withheld by the issuer on 2026-07-31 to satisfy tax withholding obligations on PSU vesting
Reference value for tax withholding 5.0900 per share Per-share value used for the 199209 shares withheld to cover tax obligations
performance-based restricted stock units (PSUs) financial
"performance criteria underlying an award of performance-based restricted stock units (PSUs)"
Compensation Committee financial
"acquired upon the certification of the Compensation Committee of the Issuer's Board"
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
tax withholding obligations financial
"shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider stock transactions did Strata Critical Medical (SRTA) report for William A. Heyburn?
The filing shows PSU-related equity grants and tax-share withholding. On July 30, 2026, Heyburn acquired 181,071 and 179,160 shares from PSU vesting, and on July 31, 199,209 shares were withheld to cover related tax obligations.

Were the Strata Critical Medical (SRTA) transactions open-market buys or sells?
No open-market trades are reported. The acquisitions reflect share delivery from PSU awards at a $0.0000 grant price, and the disposition reflects shares withheld by the issuer to satisfy tax obligations arising from the PSU vesting.

What PSUs vested for Strata Critical Medical (SRTA) executive William A. Heyburn?
Shares were acquired upon certification that performance criteria for two PSU awards were met. One award was granted on March 8, 2024 and delivered 181,071 shares; the other, granted on March 20, 2025, delivered 179,160 shares.

Why were 199,209 Strata Critical Medical (SRTA) shares disposed of in this Form 4?
The 199,209 shares were not market sold; they were withheld by the issuer to cover tax withholding obligations connected to the vesting of PSUs, at a reference value of about $5.09 per share.

Does the Strata Critical Medical (SRTA) Form 4 show large net buying or selling by the executive?
The reported activity is compensation-related rather than trading-driven. It combines PSU-based share delivery and tax withholding, resulting in both acquired and disposed shares, with the data summary indicating a neutral net buy/sell share count for the period.

Who is the insider involved in these Strata Critical Medical (SRTA) transactions and what is his role?
The reporting person is William A. Heyburn, who serves as Co-CEO and CFO of Strata Critical Medical, Inc. The Form 4 records his direct ownership transactions in the company’s Class A common stock related to PSU vesting and tax withholding.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Heyburn William A.
(Last)(First)(Middle)
C/O STRATA CRITICAL MEDICAL, INC.
666 THIRD AVENUE, 25TH FLOOR
(Street)
NEW YORK NEW YORK 10017
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Co-CEO and CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A common stock, $0.0001 par value per share07/30/2026A181,071(1)A$01,730,068D
Class A common stock, $0.0001 par value per share07/30/2026A179,160(2)A$01,909,228D
Class A common stock, $0.0001 par value per share07/31/2026F199,209(3)D$5.091,710,019D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares that were acquired upon the certification of the Compensation Committee of the Issuer's Board of Directors of the satisfaction of performance criteria underlying an award of performance-based restricted stock units ("PSUs") granted to the Reporting Person on March 8, 2024.
2. Represents shares that were acquired upon the certification of the Compensation Committee of the Issuer's Board of Directors of the satisfaction of performance criteria underlying an award of performance-based restricted stock units ("PSUs") granted to the Reporting Person on March 20, 2025.
3. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of PSUs.
Remarks:
/s/ Melissa M. Tomkiel, as attorney-in-fact for William A. Heyburn08/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR